Celgene price target raised to $96 from $82 at Cantor


Cantor increased its target on Celgene after the company announced that its ABRAXANE has met the primary endpoint of overall survival in a trial of metastatic pancreatic cancer. The firm believes that the company has several catalysts that can accelerate its revenue and EPS growth ,and it reiterates a Buy rating.

View Comments (0)